15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 11.2% per year over the past 5 years.
Operating margin has contracted, at -7.2% in the latest year.
Financial health
Total debt has grown slower than revenue (-9.0% vs 11.2% per year).
The company is unprofitable; at its current free-cash-flow burn it has roughly 18.9 years of cash runway.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$41M
-$3M
62.3%
-7.2%
-$470112
—
$9M
2024
$34M
-$6M
63.4%
-19.2%
-$2M
—
$10M
2023
$29M
-$14M
58.6%
-36.0%
-$6M
—
$11M
2022
$28M
-$9M
55.1%
-38.6%
-$8M
—
$17M
2021
$23M
-$5M
58.6%
-29.9%
-$5M
—
$25M
2020
$24M
-$1M
61.8%
-5.2%
-$2M
—
$27M
2019
$23M
$564349
64.1%
2.5%
$119446
—
$6M
2018
$17M
$910570
62.3%
6.7%
$1M
—
$4M
2017
—
$904957
—
—
$762095
—
$4M
2017
—
-$534999
—
—
—
—
$3M
2016
—
$782864
—
—
—
—
$4M
2015
—
$753117
—
—
—
—
$3M
2014
—
$703429
—
—
—
—
$2M
2013
—
$725763
—
—
—
$439306
$2M
2012
—
$815893
—
—
—
$482800
$2M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$12M
-$807078
61.5%
-7.4%
-$31500
—
$9M
Dec '25
$11M
-$486856
62.6%
-5.0%
$686974
—
$9M
Sep '25
$10M
-$777966
60.2%
-8.3%
$12973
—
$8M
Jun '25
$10M
-$206867
63.5%
-3.1%
-$489154
—
$8M
Mar '25
$10M
-$1M
62.8%
-12.9%
-$680905
—
$9M
Dec '24
$9M
-$2M
62.9%
-18.0%
$983182
—
$10M
Sep '24
$8M
-$2M
63.4%
-20.8%
-$2M
—
$9M
Jun '24
$8M
-$988715
65.0%
-14.1%
-$112949
—
$10M
Mar '24
$8M
-$2M
62.3%
-23.9%
-$479803
—
$11M
Dec '23
$7M
-$7M
60.3%
-30.6%
$900753
—
$11M
Sep '23
$7M
-$1M
62.0%
-25.6%
-$1M
—
$11M
Jun '23
$7M
-$2M
56.1%
-46.5%
-$256578
—
$12M
Mar '23
$7M
-$2M
56.1%
-41.3%
-$5M
—
$12M
Dec '22
$7M
-$2M
55.5%
-34.2%
$1M
—
$17M
Sep '22
$8M
-$1M
55.7%
-19.7%
-$3M
—
$16M
Jun '22
$7M
-$3M
51.1%
-55.2%
-$4M
—
$18M
Mar '22
$6M
-$3M
58.0%
-50.1%
-$3M
—
$23M
Dec '21
$6M
-$1M
59.0%
-32.6%
-$761590
—
$25M
Sep '21
$6M
-$1M
57.9%
-21.9%
-$975725
—
$26M
Jun '21
$6M
-$1M
58.1%
-25.0%
-$227243
—
$27M
Valuation over time
How the market has priced KRMD against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 6.9× (Mar '23) to 4.8× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is KRMD growing its revenue and profit?
Over the past 5 years, KORU Medical Systems, Inc.'s revenue has grown 11.2% per year. These are computed facts, not advice.
How much debt does KRMD have?
As of FY2025, KORU Medical Systems, Inc. reported — of total debt against $9M of cash.
What is KRMD's profit margin?
In FY2025, gross margin was 62.3%, operating margin -7.2%, and net margin -6.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.